Table 3.
GPs’ choices of prescribing and deprescribing related to their perception of the RBR for females with multiple chronic diseases and multiple prescription drugsa
| GPs judging the RBR to be unfavourableb | GPs reporting that stopping is requiredc | GPs choosing not to stop the drug while judging its RBR to be unfavourable | |
|---|---|---|---|
| Treatment | n/N (%) | n/N (%) | n/N (%) |
| Lorazepam | 929/1025 (90.6) | 934/1032 (90.5) | 70/1183 (5.9) |
| Paracetamol and tramadol | 697/1016 (68.6) | 562/1011 (55.6) | 176/1183 (14.9) |
| Amitriptyline | 785/1010 (77.7) | 673/1006 (66.9) | 147/1183 (12.4) |
| Rosuvastatind | 135/477 (28.4) | 124/487 (25.4) | 38/1183 (3.2) |
a
Weighted data.
b
Among the GPs reporting that some prescription drugs presented more risks than benefits (88.6% of all responding GPs).
c
Among the GPs reporting that some prescription drugs should be stopped (90.0% of all responding GPs).
d
Among the GPs questioned about a version of the clinical vignette, including a history of stroke. RBR = risk–benefit ratio.